Evidence map›Paper›PMID 29950423›Full record

ArticleJournal of virology2018

HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.

Zanele Ditse, Maximilian Muenchhoff, Emily Adland, Pieter Jooste, Philip Goulder, Penny L Moore, Lynn Morris

Open access · hybridAbstract read
In one paragraph

Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Research Toward a Cure for Perinatal HIV.Clinics in perinatology · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Zanele DitseCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
Maximilian MuenchhoffDepartment of Paediatrics and HIV Pathogenesis Programme, University of Oxford, Oxford, United Kingdom.
Emily AdlandDepartment of Paediatrics and HIV Pathogenesis Programme, University of Oxford, Oxford, United Kingdom.
Pieter JoostePediatric Department, Kimberley Hospital, Northern Cape, South Africa.
Philip GoulderDepartment of Paediatrics and HIV Pathogenesis Programme, University of Oxford, Oxford, United Kingdom.
Penny L MooreCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa pennym@nicd.ac.za lynnm@nicd.ac.za.
Lynn MorrisCentre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa pennym@nicd.ac.za lynnm@nicd.ac.za.
University of Oxford · GBUniversity of the Witwatersrand · ZAGerman Center for Infection Research · DEKimberley Hospital · ZAUniversity of KwaZulu-Natal · ZA

Funding

Maximising Cure Potential in Paediatric HIV InfectionR01AI133673 · NIAID · UNIVERSITY OF OXFORD · PI GOULDER, PHILIP J · 2017 to 2021
$1.4M
CAPRISA HIV-1 neutralizing antibodies: Harnessing ontogeny for immunogen designU01AI116086 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI KWONG, PETER D, MASCOLA, JOHN R · 2015 to 2019
$874k
NIAID NIH HHS R01 AI133673NIAID NIH HHS U01 AI116086
6 · The paper itself

Abstract

We have previously shown that HIV-1-infected children develop broader and more potent neutralizing antibody responses than adults. This study aimed to determine the antibody specificities in 16 HIV-1 subtype C-infected children who displayed exceptional neutralization breadth on a 22-multisubtype virus panel. All children were antiretroviral treatment (ART) naive with normal CD4 counts despite being infected for a median of 10.1 years with high viral loads. The specificity of broadly neutralizing antibodies (bNAbs) was determined using epitope-ablating mutants, chimeric constructs, and depletion or inhibition of activity with peptides and glycoproteins. We found that bNAbs in children largely targeted previously defined epitopes, including the V2-glycan, V3-glycan, CD4bs, and gp120-gp41 interface. Remarkably, 63% of children had antibodies targeting 2 or 3 and, in one case, 4 of these bNAb epitopes. Longitudinal analysis of plasma from a mother-child pair over 9 years showed that while they both had similar neutralization profiles, the antibody specificities differed. The mother developed antibodies targeting the V2-glycan and CD4bs, whereas bNAb specificities in the child could not be mapped until 6 years, when a minor V2-glycan response appeared. The child also developed high-titer membrane-proximal external region (MPER) binding antibodies not seen in the mother, although these were not a major bNAb specificity. Overall, exceptional neutralization breadth in this group of children may be the result of extended exposure to high antigenic load in the context of an intact immune system, which allowed for the activation of multiple B cell lineages and the generation of polyclonal responses targeting several bNAb epitopes.

Indexed as

AdolescentAdultAntibodies, NeutralizingChildEpitope MappingEpitopesHIV-1HIV AntibodiesHIV InfectionsHumansLongitudinal StudiesYoung AdultAntibodies, NeutralizingEpitopesHIV AntibodiesbNAbsepitope mappingHIV-1 subtype CHIV envelope targetsHIV vaccinesmother-child transmissionneutralization breadthneutralizing antibodiespediatric immunology

Identifiers

PMID29950423
PMCPMC6096808
OpenAlexW2811354203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.